Journal article · 2026

Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer

Sara M. Tolaney, Evandro de Azambuja, Kevin M. Kalinsky, Sherene Loi, Sung‐Bae Kim, Clinton Yam, Bernardo Leon Rapoport, Seock‐Ah Im, Barbara Pistilli, Wassim M. McHayleh, David W. Cescon, Junichiro Watanabe and 8 more

New England Journal of Medicine, 394(4), 354–366 · Published 21 January 2026 · DOI 10.1056/nejmoa2508959

View at the publisherCite this paper

In brief

“Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer” is a 2026 journal article by Sara M. Tolaney and 19 co-authors, published in New England Journal of Medicine. OpenAlex counts 130 citations as of 17 November 2026, which puts it in the top 1% of works published in 2026 by citations. The publisher's version is not open access, and OpenAlex records no free legal copy.

Citations
130
Most cited in
2026 (129)
Field-weighted impact
219.97
References
17
Authors
20

Abstract

BACKGROUND: Triple-negative breast cancer is an aggressive breast cancer subtype, and there remains an unmet need to improve outcomes in patients with previously untreated, programmed death ligand 1 (PD-L1)-positive, locally advanced unresectable or metastatic triple-negative breast cancer. METHODS: In this phase 3, open-label, international trial, we randomly assigned patients in a 1:1 ratio to receive… Read the full abstract at the publisher.

Excerpt. This paper is not open access.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Tolaney, S. M., de Azambuja, E., Kalinsky, K. M., Loi, S., Kim, S., Yam, C., Rapoport, B. L., Im, S., Pistilli, B., McHayleh, W. M., Cescon, D. W., Watanabe, J., Bañuelas, M. A. L., Freitas‐Júnior, R., Bofill, J. S., Afshari, M., Gary, D., Wang, L., Lai, C., & Schmid, P. (2026). Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer. New England Journal of Medicine, 394(4), 354–366. https://doi.org/10.1056/nejmoa2508959

MLA 9

Tolaney, Sara M., et al. “Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer.” New England Journal of Medicine, vol. 394, no. 4, 2026, pp. 354–366. https://doi.org/10.1056/nejmoa2508959.

Chicago

Tolaney, Sara M., Evandro de Azambuja, Kevin M. Kalinsky, Sherene Loi, Sung‐Bae Kim, Clinton Yam, Bernardo Leon Rapoport, et al. 2026. “Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer.” New England Journal of Medicine 394 (4): 354–366. https://doi.org/10.1056/nejmoa2508959.

Harvard

Tolaney, S. M. et al. (2026) ‘Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer’, New England Journal of Medicine, 394(4), pp. 354–366. doi:10.1056/nejmoa2508959.

IEEE

S. M. Tolaney et al., “Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer,” New England Journal of Medicine, vol. 394, no. 4, pp. 354–366, 2026, doi: 10.1056/nejmoa2508959.

BibTeX

@article{tolaney2026sacituzumab,
  title     = {{Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer}},
  author    = {Tolaney, Sara M. and de Azambuja, Evandro and Kalinsky, Kevin M. and Loi, Sherene and Kim, Sung‐Bae and Yam, Clinton and Rapoport, Bernardo Leon and Im, Seock‐Ah and Pistilli, Barbara and McHayleh, Wassim M. and Cescon, David W. and Watanabe, Junichiro and Bañuelas, Manuel Alejandro Lara and Freitas‐Júnior, Ruffo and Bofill, Javier Salvador and Afshari, Maryam and Gary, Dianna and Wang, Lu and Lai, Catherine and Schmid, Peter},
  journal   = {New England Journal of Medicine},
  year      = {2026},
  volume    = {394},
  number    = {4},
  pages     = {354--366},
  doi       = {10.1056/nejmoa2508959},
  url       = {https://doi.org/10.1056/nejmoa2508959}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies

  • sacituzumab govitecan
  • pembrolizumab
  • triple-negative breast cancer
  • PD-L1-positive
  • metastatic breast cancer
  • combination immunotherapy
  • progression-free survival
  • objective response

Work with this paper

Most-cited papers in Biochemistry, Genetics and Molecular Biology

All highly cited Biochemistry, Genetics and Molecular Biology papers

Questions about this paper

How do I cite this paper in APA style?

Tolaney, S. M., de Azambuja, E., Kalinsky, K. M., Loi, S., Kim, S., Yam, C., Rapoport, B. L., Im, S., Pistilli, B., McHayleh, W. M., Cescon, D. W., Watanabe, J., Bañuelas, M. A. L., Freitas‐Júnior, R., Bofill, J. S., Afshari, M., Gary, D., Wang, L., Lai, C., & Schmid, P. (2026). Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer. New England Journal of Medicine, 394(4), 354–366. https://doi.org/10.1056/nejmoa2508959

How many times has this paper been cited?

130 times, according to OpenAlex on 17 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

OpenAlex records no free legal copy. Check your library's access, the authors' pages or a repository, or ask the corresponding author for a copy.

Who wrote this paper?

Sara M. Tolaney, Evandro de Azambuja, Kevin M. Kalinsky, Sherene Loi, Sung‐Bae Kim, Clinton Yam, Bernardo Leon Rapoport, Seock‐Ah Im, Barbara Pistilli, Wassim M. McHayleh, David W. Cescon, Junichiro Watanabe and 8 more.

What is the DOI of this paper?

10.1056/nejmoa2508959, permanently at https://doi.org/10.1056/nejmoa2508959. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 17 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.